These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 5519378)

  • 1. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C; Buffatti PF; Bazzan A; Lion P
    Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management of Parkinson's syndrome using levadopa. Results of a long-term study].
    Wälzholz U
    Dtsch Med Wochenschr; 1972 Apr; 97(17):686 passim. PubMed ID: 4554502
    [No Abstract]   [Full Text] [Related]  

  • 4. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract]   [Full Text] [Related]  

  • 7. [L-Dopa therapy in Parkinson's disease. A double-blind study].
    Worm-Petersen J; Dupont E; Mikkelsen B
    Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651
    [No Abstract]   [Full Text] [Related]  

  • 8. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 9. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of L-dopa treatment and its principal side effects in aged subjects].
    Antonini F; Baroni A; Bucalossi A; Roveyaz L
    Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 12. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 13. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of Parkinson's syndrome with L-dopa. In operated and nonoperated cases].
    Pimenta Ada M; Friguglietti DJ
    Rev Bras Med; 1971 Sep; 28(9):481-96. PubMed ID: 5139650
    [No Abstract]   [Full Text] [Related]  

  • 15. A year's experience of L-DOPA in the treatment of Parkinson's disease.
    Guidetti B; Giuffrè R
    Acta Neurochir (Wien); 1971; 24(2):81-8. PubMed ID: 5112463
    [No Abstract]   [Full Text] [Related]  

  • 16. [Considerations on hyperkinesis caused by L-dopa: significance of the biochemical deficit and anatomical deficit].
    Pinelli P
    Arch Psicol Neurol Psichiatr; 1970; 31(5):405-16. PubMed ID: 5502810
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 19. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-term treatment of Parkinsonism with L-dopa].
    Presthus J; Holmsen R
    Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.